Marvel Biosciences Corp Cash Flow-to-Debt Ratio
Marvel Biosciences Corp cash flow-to-debt ratio. Marvel Biosciences Corp (MRVL) has a Cash Flow-to-Debt Ratio of -0.04x as of October 2025, meaning its operating cash flow of CA$-178.46K could theoretically repay 0% of its total liabilities (CA$4.33 Million) in one year. See Marvel Biosciences Corp (MRVL) financial flexibility to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Marvel Biosciences Corp (2020–2025)
Cash flow-to-debt ratio of Marvel Biosciences Corp from 2020 to 2025. Historical debt coverage capacity for Marvel Biosciences Corp across 6 annual periods. Also explore Marvel Biosciences Corp annual equity growth to track the company's year-over-year net asset growth rate.
Marvel Biosciences Corp Cash Flow-to-Debt Ratio by Year (2020–2025)
Marvel Biosciences Corp cash flow-to-debt ratio by year from 2020 to 2025. Year-by-year debt coverage analysis for Marvel Biosciences Corp. For the full cash flow conversion analysis, see how efficiently does Marvel Biosciences Corp generate cash.
| Year | CF-to-Debt Ratio | Operating CF (CAD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.27x | CA$-1.15 Million | CA$4.33 Million | ▲ +25.3% |
| 2024 | -0.36x | CA$-1.18 Million | CA$3.32 Million | ▲ +36.1% |
| 2023 | -0.56x | CA$-1.33 Million | CA$2.39 Million | ▲ +81.8% |
| 2022 | -3.06x | CA$-2.19 Million | CA$718.00K | ▲ +74.9% |
| 2021 | -12.19x | CA$-1.37 Million | CA$112.48K | ▼ -300.9% |
| 2020 | -3.04x | CA$-538.53K | CA$177.18K | — |